Drug intelligence / Profile preview

IN 10 003 formulation B

Development stage: Phase 2
Modality: Small Molecules

Overview

No publicly available information was found for a drug specifically named "IN 10 003 formulation B" in major drug databases or regulatory sources. The name appears to be a code or internal designation, possibly referring to an investigational product or a specific pharmaceutical formulation. The term "formulation B" suggests it is one of several versions of the same active ingredient or combination, but without further context, details about its mechanism of action, indication, developer, or manufacturer are unknown.

Beyond the preview

Go deeper on IN 10 003 formulation B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IN 10 003 formulation B.

Explore the full profile